“Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s688. doi:10.25251/jy4cvn36.